Giles HV - Search Results

1

Redefining nonmeasurable multiple myeloma using mass spectrometry.

Giles HV, Cook MA, Drayson MT, Cook G, Wright NJ, North SJ, Harding S, Cairns DA, Hockaday A, Kaiser MF, Moss P, Davies FE, Morgan GJ, Jackson G, Pratt G. Giles HV, et al. Blood. 2022 Feb 10;139(6):946-950. doi: 10.1182/blood.2021013794. Blood. 2022. PMID: 34871382 Free article. No abstract available.

2

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ. Brioli A, et al. Blood. 2014 May 29;123(22):3414-9. doi: 10.1182/blood-2013-12-542662. Epub 2014 Apr 14. Blood. 2014. PMID: 24733348 Free article.

3

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.

Yadav P, Cockwell P, Cook M, Pinney J, Giles H, Aung YS, Cairns D, Owen RG, Davies FE, Jackson GH, Child JA, Morgan GJ, Drayson MT. Yadav P, et al. BMC Nephrol. 2018 Jul 13;19(1):178. doi: 10.1186/s12882-018-0962-x. BMC Nephrol. 2018. PMID: 30012107 Free PMC article. Clinical Trial.

4

Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment.

Giles H, Pratt G. Giles H, et al. Br J Haematol. 2021 Feb;192(3):420-422. doi: 10.1111/bjh.17277. Epub 2020 Dec 20. Br J Haematol. 2021. PMID: 33341927 Free article. No abstract available.

5

The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?

Giles HV, Wechalekar A, Pratt G. Giles HV, et al. Br J Haematol. 2022 Aug;198(4):641-653. doi: 10.1111/bjh.18226. Epub 2022 May 5. Br J Haematol. 2022. PMID: 35514140 Review.

6

Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma.

Gudgeon N, Giles H, Bishop EL, Fulton-Ward T, Escribano-Gonzalez C, Munford H, James-Bott A, Foster K, Karim F, Jayawardana D, Mahmood A, Cribbs AP, Tennant DA, Basu S, Pratt G, Dimeloe S. Gudgeon N, et al. Blood Adv. 2023 Oct 24;7(20):6035-6047. doi: 10.1182/bloodadvances.2023009890. Blood Adv. 2023. PMID: 37276076 Free PMC article.

7

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.

Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Bomsztyk J, et al. Among authors: giles hv. Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399. Blood. 2024. PMID: 38194690

8

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

Giles HV, Drayson MT, Kishore B, Pawlyn C, Kaiser M, Cook G, de Tute R, Owen RG, Cairns D, Menzies T, Davies FE, Morgan GJ, Pratt G, Jackson GH. Giles HV, et al. Blood Cancer J. 2024 Mar 18;14(1):50. doi: 10.1038/s41408-024-00995-y. Blood Cancer J. 2024. PMID: 38499538 Free PMC article.

9

Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.

Maybury BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, Qureshi I, Riley JWE, Talbot G, Moosai S, Giles HV Dr, Chadderton N Mrs, Dowds J, Rakesh P, Crosland H, Haslam A, Lane S, Vega Gonzalez M, Davies D, Cherian G, Shenouda A, Kaudlay Sathyanarayana PK, Starczynski J, Rudzki Z, Chaganti S. Maybury BD, et al. Among authors: giles hv dr. Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048. Online ahead of print. Blood. 2024. PMID: 38648564

10

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.

Khanim FL, Merrick BA, Giles HV, Jankute M, Jackson JB, Giles LJ, Birtwistle J, Bunce CM, Drayson MT. Khanim FL, et al. Among authors: giles hv. Blood Cancer J. 2011 Oct;1(10):e39. doi: 10.1038/bcj.2011.38. Epub 2011 Oct 21. Blood Cancer J. 2011. PMID: 22829072 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page